Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0633 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Arm 1: Drug |
| Name | Type | Description |
|---|---|---|
| MK0633 | DRUG | Single dose MK0633 100mg po in the fed state administered during a 4-wk study. |
| Comparator: MK0633 | DRUG | A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight. |
Inclusion Criteria: * Patients with plaque in coronary or leg arteries, known as atherosclerosis or peripheral vascular disease * Inflammatory marker found in your blood, known as hsCRP \> 0.5 mg/L Exclusion Criteria: * Age \< 40 or \> 85 * Female * Heart attack, coronary artery bypass, stroke or...
MK0633 is an investigational small molecule being studied for asthma and atherosclerosis. Clinical trials have evaluated the drug in patients with atherosclerosis and in asthmatic children. It is not approved and remains in clinical development.
MK0633 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company has sponsored clinical trials of the drug in asthma and atherosclerosis.
MK0633 is in Phase 1 clinical development. Completed trials include Phase 1 studies in asthmatic children and a Phase 2 study in atherosclerosis. The drug remains investigational and has not been approved.
MK0633 has been studied in several completed trials, including NCT00421278 in atherosclerosis, NCT00646789 and NCT00751413 in asthmatic children, and NCT00768170 in Japanese asthmatic children. All trials are completed.
MK0633 is also referred to as 0633 in clinical trial titles. For example, the atherosclerosis trial is titled "The Effect of MK 0633 in Patients With Atherosclerosis (0633-008)." Both names refer to the same drug.